Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Many congratulations to Prof Adrian Harris (Department of Oncology), who has become a Fellow of the Association of Cancer Physicians.

Professor Harris was awarded the honour of Fellowship of the Association of Cancer Physicians (FACP) for outstanding contributions to the development of medical oncology and cancer research.

Adrian Harris portraitThis is awarded based on translational research, particularly breast cancer and pathways of hypoxia, angiogenesis and endocrine regulation of growth. He also established two departments of medical oncology, the first time in Newcastle upon Tyne in 1982 and then one in Oxford in 1989. In both, he established phase I units as part of a CRUK national programme, with a particular emphasis on pharmacodynamics and sampling of tumours during studies, to help direct therapies. He took a major role in developing antiangiogenic therapy and investigating new pathways that could mediate resistance to current drugs.

He has trained over 50 DPhil students in medical oncology, clinical and cancer therapy. He also was involved in the early development of genetic classification of breast cancer and many refinements based on new discoveries of the interactions with angiogenesis and hypoxia biology.

 

Similar stories

Scientists find genetic ‘marker’ linked to serious side-effects from skin cancer treatment

New research from the Fairfax Group has identified a genetic marker that could be used to predict a patient’s risk of developing serious side-effects when undergoing immunotherapy treatment for metastatic melanoma.

Seven research groups secure LEAF Sustainability Awards

The Laboratory Efficiency Assessment Framework (LEAF) aims to support research groups to embed sustainability into their work.

Blood tests may predict response to immunotherapy for melanoma

A study from the Fairfax lab provides new insight into the factors that determine patient response to Immune Checkpoint Blockers, a common immunotherapy treatment for melanoma.

New “molecular fibres” may help cells repair DNA

Research by the Blackford group has for the first time observed molecular fibres that may hold together sections of broken DNA in mitosis.

MRC WIMM researchers talk about their research on rare diseases

To mark rare disease day we asked our researchers to tell us more about the rare conditions that they study, and why their research is important.

MRC HIU Group Leader in team shortlisted for £20m CRUK Grand Challenge Award

An international team of scientists has been shortlisted out of 134 applications spanning 41 countries.